nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0797	0.152	CbGbCtD
Dabrafenib—ABCG2—Dactinomycin—uterine cancer	0.0786	0.15	CbGbCtD
Dabrafenib—ABCG2—Carboplatin—uterine cancer	0.0528	0.101	CbGbCtD
Dabrafenib—CYP2C8—Progesterone—uterine cancer	0.0528	0.101	CbGbCtD
Dabrafenib—ABCG2—Etoposide—uterine cancer	0.0443	0.0848	CbGbCtD
Dabrafenib—ABCB1—Progesterone—uterine cancer	0.0357	0.0683	CbGbCtD
Dabrafenib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0323	0.0618	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—uterine cancer	0.0302	0.0578	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—uterine cancer	0.0283	0.0542	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—uterine cancer	0.0236	0.0452	CbGbCtD
Dabrafenib—CYP3A4—Progesterone—uterine cancer	0.0214	0.0409	CbGbCtD
Dabrafenib—ABCB1—Etoposide—uterine cancer	0.016	0.0306	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—uterine cancer	0.0109	0.0209	CbGbCtD
Dabrafenib—CYP3A4—Etoposide—uterine cancer	0.00958	0.0183	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—uterine cancer	0.00653	0.0125	CbGbCtD
Dabrafenib—NEK11—uterine cervix—uterine cancer	0.0064	0.0637	CbGeAlD
Dabrafenib—NEK11—uterus—uterine cancer	0.00534	0.0531	CbGeAlD
Dabrafenib—NEK11—female reproductive system—uterine cancer	0.0048	0.0477	CbGeAlD
Dabrafenib—LIMK1—decidua—uterine cancer	0.00437	0.0434	CbGeAlD
Dabrafenib—NEK11—female gonad—uterine cancer	0.00437	0.0434	CbGeAlD
Dabrafenib—LIMK1—vagina—uterine cancer	0.00311	0.0309	CbGeAlD
Dabrafenib—NEK11—lymph node—uterine cancer	0.00281	0.0279	CbGeAlD
Dabrafenib—BRAF—endometrium—uterine cancer	0.00256	0.0255	CbGeAlD
Dabrafenib—RAF1—myometrium—uterine cancer	0.00242	0.0241	CbGeAlD
Dabrafenib—SIK1—uterine cervix—uterine cancer	0.00237	0.0236	CbGeAlD
Dabrafenib—BRAF—uterus—uterine cancer	0.00236	0.0235	CbGeAlD
Dabrafenib—SIK1—decidua—uterine cancer	0.00226	0.0225	CbGeAlD
Dabrafenib—SIK1—renal system—uterine cancer	0.00222	0.0221	CbGeAlD
Dabrafenib—SIK1—endometrium—uterine cancer	0.00214	0.0213	CbGeAlD
Dabrafenib—SIK1—mammalian vulva—uterine cancer	0.00207	0.0206	CbGeAlD
Dabrafenib—LIMK1—lymph node—uterine cancer	0.00201	0.02	CbGeAlD
Dabrafenib—SIK1—uterus—uterine cancer	0.00198	0.0196	CbGeAlD
Dabrafenib—BRAF—female gonad—uterine cancer	0.00193	0.0192	CbGeAlD
Dabrafenib—BRAF—vagina—uterine cancer	0.00192	0.0191	CbGeAlD
Dabrafenib—RAF1—epithelium—uterine cancer	0.0019	0.0189	CbGeAlD
Dabrafenib—RAF1—uterine cervix—uterine cancer	0.00189	0.0188	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—uterine cancer	0.00183	0.0182	CbGeAlD
Dabrafenib—RAF1—decidua—uterine cancer	0.0018	0.0179	CbGeAlD
Dabrafenib—SIK1—female reproductive system—uterine cancer	0.00178	0.0177	CbGeAlD
Dabrafenib—RAF1—renal system—uterine cancer	0.00176	0.0176	CbGeAlD
Dabrafenib—RAF1—endometrium—uterine cancer	0.00171	0.017	CbGeAlD
Dabrafenib—SLCO1B3—vagina—uterine cancer	0.00165	0.0164	CbGeAlD
Dabrafenib—RAF1—mammalian vulva—uterine cancer	0.00165	0.0164	CbGeAlD
Dabrafenib—SIK1—female gonad—uterine cancer	0.00162	0.0161	CbGeAlD
Dabrafenib—RAF1—uterus—uterine cancer	0.00157	0.0156	CbGeAlD
Dabrafenib—RAF1—female reproductive system—uterine cancer	0.00141	0.0141	CbGeAlD
Dabrafenib—SLCO1B1—renal system—uterine cancer	0.00132	0.0131	CbGeAlD
Dabrafenib—RAF1—female gonad—uterine cancer	0.00129	0.0128	CbGeAlD
Dabrafenib—RAF1—vagina—uterine cancer	0.00128	0.0127	CbGeAlD
Dabrafenib—BRAF—lymph node—uterine cancer	0.00124	0.0123	CbGeAlD
Dabrafenib—SLCO1B1—female reproductive system—uterine cancer	0.00106	0.0105	CbGeAlD
Dabrafenib—SIK1—lymph node—uterine cancer	0.00104	0.0103	CbGeAlD
Dabrafenib—SLC22A8—renal system—uterine cancer	0.00103	0.0102	CbGeAlD
Dabrafenib—ABCG2—myometrium—uterine cancer	0.001	0.00997	CbGeAlD
Dabrafenib—RAF1—lymph node—uterine cancer	0.000827	0.00822	CbGeAlD
Dabrafenib—ABCG2—uterine cervix—uterine cancer	0.00078	0.00776	CbGeAlD
Dabrafenib—CYP2C8—renal system—uterine cancer	0.000751	0.00747	CbGeAlD
Dabrafenib—ABCG2—decidua—uterine cancer	0.000743	0.00739	CbGeAlD
Dabrafenib—CYP2C8—endometrium—uterine cancer	0.000726	0.00722	CbGeAlD
Dabrafenib—ABCG2—endometrium—uterine cancer	0.000706	0.00702	CbGeAlD
Dabrafenib—ABCG2—mammalian vulva—uterine cancer	0.000683	0.00679	CbGeAlD
Dabrafenib—ABCG2—uterus—uterine cancer	0.00065	0.00647	CbGeAlD
Dabrafenib—CYP2C8—female reproductive system—uterine cancer	0.000601	0.00598	CbGeAlD
Dabrafenib—CYP2C8—vagina—uterine cancer	0.000544	0.00541	CbGeAlD
Dabrafenib—ABCG2—female gonad—uterine cancer	0.000532	0.00529	CbGeAlD
Dabrafenib—ABCG2—vagina—uterine cancer	0.000529	0.00526	CbGeAlD
Dabrafenib—CYP3A4—renal system—uterine cancer	0.000508	0.00506	CbGeAlD
Dabrafenib—ABCB1—myometrium—uterine cancer	0.000494	0.00492	CbGeAlD
Dabrafenib—CYP3A4—female reproductive system—uterine cancer	0.000407	0.00405	CbGeAlD
Dabrafenib—ABCB1—epithelium—uterine cancer	0.000388	0.00386	CbGeAlD
Dabrafenib—ABCB1—uterine cervix—uterine cancer	0.000385	0.00383	CbGeAlD
Dabrafenib—ABCB1—decidua—uterine cancer	0.000367	0.00365	CbGeAlD
Dabrafenib—ABCB1—renal system—uterine cancer	0.00036	0.00358	CbGeAlD
Dabrafenib—Anaemia—Dactinomycin—uterine cancer	0.000351	0.00172	CcSEcCtD
Dabrafenib—ABCB1—endometrium—uterine cancer	0.000348	0.00346	CbGeAlD
Dabrafenib—Abdominal pain—Progesterone—uterine cancer	0.000347	0.0017	CcSEcCtD
Dabrafenib—Body temperature increased—Progesterone—uterine cancer	0.000347	0.0017	CcSEcCtD
Dabrafenib—Hyperkalaemia—Epirubicin—uterine cancer	0.000347	0.0017	CcSEcCtD
Dabrafenib—Renal failure—Etoposide—uterine cancer	0.000346	0.0017	CcSEcCtD
Dabrafenib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000346	0.0017	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000343	0.00168	CcSEcCtD
Dabrafenib—Stomatitis—Etoposide—uterine cancer	0.000343	0.00168	CcSEcCtD
Dabrafenib—Creatinine increased—Doxorubicin—uterine cancer	0.000343	0.00168	CcSEcCtD
Dabrafenib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000343	0.00168	CcSEcCtD
Dabrafenib—Influenza like illness—Epirubicin—uterine cancer	0.000343	0.00168	CcSEcCtD
Dabrafenib—ABCG2—lymph node—uterine cancer	0.000342	0.0034	CbGeAlD
Dabrafenib—Leukopenia—Dactinomycin—uterine cancer	0.00034	0.00167	CcSEcCtD
Dabrafenib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00034	0.00167	CcSEcCtD
Dabrafenib—ABCB1—mammalian vulva—uterine cancer	0.000337	0.00335	CbGeAlD
Dabrafenib—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.000326	0.0016	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000325	0.0016	CcSEcCtD
Dabrafenib—Myalgia—Dactinomycin—uterine cancer	0.000324	0.00159	CcSEcCtD
Dabrafenib—Hypersensitivity—Progesterone—uterine cancer	0.000323	0.00159	CcSEcCtD
Dabrafenib—ABCB1—uterus—uterine cancer	0.000321	0.00319	CbGeAlD
Dabrafenib—Hyperkalaemia—Doxorubicin—uterine cancer	0.000321	0.00157	CcSEcCtD
Dabrafenib—Rash maculo-papular—Epirubicin—uterine cancer	0.000321	0.00157	CcSEcCtD
Dabrafenib—Neoplasm—Epirubicin—uterine cancer	0.000319	0.00157	CcSEcCtD
Dabrafenib—Influenza like illness—Doxorubicin—uterine cancer	0.000317	0.00156	CcSEcCtD
Dabrafenib—Asthenia—Progesterone—uterine cancer	0.000315	0.00155	CcSEcCtD
Dabrafenib—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000314	0.00154	CcSEcCtD
Dabrafenib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000314	0.00154	CcSEcCtD
Dabrafenib—Urinary tract disorder—Etoposide—uterine cancer	0.000312	0.00153	CcSEcCtD
Dabrafenib—Pruritus—Progesterone—uterine cancer	0.00031	0.00152	CcSEcCtD
Dabrafenib—Oedema—Dactinomycin—uterine cancer	0.00031	0.00152	CcSEcCtD
Dabrafenib—Urethral disorder—Etoposide—uterine cancer	0.00031	0.00152	CcSEcCtD
Dabrafenib—Infection—Dactinomycin—uterine cancer	0.000308	0.00151	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dactinomycin—uterine cancer	0.000304	0.00149	CcSEcCtD
Dabrafenib—Diarrhoea—Progesterone—uterine cancer	0.0003	0.00147	CcSEcCtD
Dabrafenib—Rash maculo-papular—Doxorubicin—uterine cancer	0.000297	0.00146	CcSEcCtD
Dabrafenib—Eye disorder—Etoposide—uterine cancer	0.000295	0.00145	CcSEcCtD
Dabrafenib—Neoplasm—Doxorubicin—uterine cancer	0.000295	0.00145	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000294	0.00144	CcSEcCtD
Dabrafenib—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000293	0.00144	CcSEcCtD
Dabrafenib—Dizziness—Progesterone—uterine cancer	0.00029	0.00142	CcSEcCtD
Dabrafenib—ABCB1—female reproductive system—uterine cancer	0.000288	0.00287	CbGeAlD
Dabrafenib—Angiopathy—Etoposide—uterine cancer	0.000287	0.00141	CcSEcCtD
Dabrafenib—Immune system disorder—Etoposide—uterine cancer	0.000285	0.0014	CcSEcCtD
Dabrafenib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000285	0.0014	CcSEcCtD
Dabrafenib—Mediastinal disorder—Etoposide—uterine cancer	0.000285	0.0014	CcSEcCtD
Dabrafenib—Chills—Etoposide—uterine cancer	0.000284	0.00139	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000283	0.00139	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Epirubicin—uterine cancer	0.000282	0.00139	CcSEcCtD
Dabrafenib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000281	0.00138	CcSEcCtD
Dabrafenib—Alopecia—Etoposide—uterine cancer	0.000279	0.00137	CcSEcCtD
Dabrafenib—Vomiting—Progesterone—uterine cancer	0.000279	0.00137	CcSEcCtD
Dabrafenib—Renal failure acute—Epirubicin—uterine cancer	0.000277	0.00136	CcSEcCtD
Dabrafenib—Rash—Progesterone—uterine cancer	0.000277	0.00136	CcSEcCtD
Dabrafenib—Dermatitis—Progesterone—uterine cancer	0.000276	0.00136	CcSEcCtD
Dabrafenib—Headache—Progesterone—uterine cancer	0.000275	0.00135	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000272	0.00134	CcSEcCtD
Dabrafenib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.00134	CcSEcCtD
Dabrafenib—Decreased appetite—Dactinomycin—uterine cancer	0.00027	0.00132	CcSEcCtD
Dabrafenib—Dermatitis bullous—Epirubicin—uterine cancer	0.000268	0.00131	CcSEcCtD
Dabrafenib—Fatigue—Dactinomycin—uterine cancer	0.000267	0.00131	CcSEcCtD
Dabrafenib—Back pain—Etoposide—uterine cancer	0.000266	0.00131	CcSEcCtD
Dabrafenib—Muscle spasms—Etoposide—uterine cancer	0.000264	0.0013	CcSEcCtD
Dabrafenib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000263	0.00129	CcSEcCtD
Dabrafenib—ABCB1—female gonad—uterine cancer	0.000262	0.00261	CbGeAlD
Dabrafenib—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000261	0.00128	CcSEcCtD
Dabrafenib—ABCB1—vagina—uterine cancer	0.000261	0.00259	CbGeAlD
Dabrafenib—Nausea—Progesterone—uterine cancer	0.000261	0.00128	CcSEcCtD
Dabrafenib—Hyponatraemia—Epirubicin—uterine cancer	0.000257	0.00126	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—uterine cancer	0.000257	0.00126	CcSEcCtD
Dabrafenib—Pain in extremity—Epirubicin—uterine cancer	0.000256	0.00126	CcSEcCtD
Dabrafenib—Anaemia—Etoposide—uterine cancer	0.000254	0.00125	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000254	0.00124	CcSEcCtD
Dabrafenib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000253	0.00124	CcSEcCtD
Dabrafenib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000251	0.00123	CcSEcCtD
Dabrafenib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00025	0.00123	CcSEcCtD
Dabrafenib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000249	0.00122	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—uterine cancer	0.000248	0.00122	CcSEcCtD
Dabrafenib—Leukopenia—Etoposide—uterine cancer	0.000246	0.00121	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—uterine cancer	0.000245	0.0012	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—uterine cancer	0.000245	0.0012	CcSEcCtD
Dabrafenib—Cough—Etoposide—uterine cancer	0.00024	0.00118	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—uterine cancer	0.00024	0.00118	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—uterine cancer	0.000238	0.00117	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—uterine cancer	0.000238	0.00117	CcSEcCtD
Dabrafenib—Hypertension—Etoposide—uterine cancer	0.000237	0.00117	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—uterine cancer	0.000237	0.00116	CcSEcCtD
Dabrafenib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000236	0.00116	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—uterine cancer	0.000235	0.00115	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—uterine cancer	0.000234	0.00115	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—uterine cancer	0.000233	0.00114	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000233	0.00114	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000231	0.00113	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—uterine cancer	0.000229	0.00112	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—uterine cancer	0.000229	0.00112	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000226	0.00111	CcSEcCtD
Dabrafenib—Infection—Etoposide—uterine cancer	0.000223	0.00109	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—uterine cancer	0.000223	0.00109	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—uterine cancer	0.000222	0.00109	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—uterine cancer	0.00022	0.00108	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—uterine cancer	0.00022	0.00108	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—uterine cancer	0.000218	0.00107	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—uterine cancer	0.000217	0.00107	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—uterine cancer	0.000217	0.00107	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—uterine cancer	0.000217	0.00106	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—uterine cancer	0.000216	0.00106	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—uterine cancer	0.000216	0.00106	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000213	0.00105	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—uterine cancer	0.000212	0.00104	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—uterine cancer	0.000212	0.00104	CcSEcCtD
Dabrafenib—Hypotension—Etoposide—uterine cancer	0.00021	0.00103	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000209	0.00103	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—uterine cancer	0.000207	0.00102	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—uterine cancer	0.000201	0.000985	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—uterine cancer	0.0002	0.00098	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—uterine cancer	0.000197	0.000968	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—uterine cancer	0.000197	0.000968	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—uterine cancer	0.000197	0.000968	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—uterine cancer	0.000196	0.00096	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—uterine cancer	0.000195	0.000958	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—uterine cancer	0.000194	0.000952	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000194	0.000951	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—uterine cancer	0.000194	0.00095	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—uterine cancer	0.000192	0.000944	CcSEcCtD
Dabrafenib—Constipation—Etoposide—uterine cancer	0.000192	0.000942	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—uterine cancer	0.000192	0.000941	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—uterine cancer	0.000191	0.00094	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—uterine cancer	0.000188	0.000923	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—uterine cancer	0.000186	0.000913	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—uterine cancer	0.000185	0.000906	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—uterine cancer	0.000184	0.000904	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—uterine cancer	0.000184	0.000901	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—uterine cancer	0.000183	0.000896	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—uterine cancer	0.000183	0.000896	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—uterine cancer	0.000179	0.000881	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—uterine cancer	0.000178	0.000874	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—uterine cancer	0.000178	0.000873	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—uterine cancer	0.000177	0.000871	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—uterine cancer	0.000177	0.000871	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—uterine cancer	0.000177	0.000871	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—uterine cancer	0.000177	0.000869	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—uterine cancer	0.000175	0.000858	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—uterine cancer	0.000174	0.000856	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—uterine cancer	0.000174	0.000854	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—uterine cancer	0.000174	0.000854	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—uterine cancer	0.000174	0.000852	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—uterine cancer	0.000172	0.000845	CcSEcCtD
Dabrafenib—ABCB1—lymph node—uterine cancer	0.000169	0.00168	CbGeAlD
Dabrafenib—Eye disorder—Epirubicin—uterine cancer	0.000166	0.000812	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—uterine cancer	0.000165	0.000812	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—uterine cancer	0.000165	0.000808	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—uterine cancer	0.000164	0.000804	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000162	0.000794	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—uterine cancer	0.000161	0.000792	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—uterine cancer	0.000161	0.00079	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—uterine cancer	0.000161	0.00079	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—uterine cancer	0.000161	0.000789	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—uterine cancer	0.000161	0.000788	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—uterine cancer	0.00016	0.000785	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—uterine cancer	0.00016	0.000783	CcSEcCtD
Dabrafenib—Chills—Epirubicin—uterine cancer	0.000159	0.00078	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—uterine cancer	0.000159	0.000779	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—uterine cancer	0.000158	0.000777	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—uterine cancer	0.000157	0.000768	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—uterine cancer	0.000155	0.000762	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—uterine cancer	0.000154	0.000757	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—uterine cancer	0.000154	0.000757	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—uterine cancer	0.000154	0.000754	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—uterine cancer	0.000153	0.000752	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—uterine cancer	0.000149	0.000732	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—uterine cancer	0.000149	0.00073	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—uterine cancer	0.000148	0.000729	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—uterine cancer	0.000148	0.000728	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—uterine cancer	0.000148	0.000726	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—uterine cancer	0.000148	0.000725	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—uterine cancer	0.000147	0.000722	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—uterine cancer	0.000146	0.000719	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—uterine cancer	0.000145	0.000713	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—uterine cancer	0.000145	0.000711	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—uterine cancer	0.000144	0.000705	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—uterine cancer	0.000143	0.0007	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—uterine cancer	0.000143	0.0007	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—uterine cancer	0.000143	0.0007	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—uterine cancer	0.000143	0.000699	CcSEcCtD
Dabrafenib—Rash—Etoposide—uterine cancer	0.000142	0.000695	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—uterine cancer	0.000141	0.000694	CcSEcCtD
Dabrafenib—Headache—Etoposide—uterine cancer	0.000141	0.00069	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—uterine cancer	0.000138	0.000677	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—uterine cancer	0.000138	0.000677	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—uterine cancer	0.000137	0.000673	CcSEcCtD
Dabrafenib—Cough—Epirubicin—uterine cancer	0.000135	0.00066	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—uterine cancer	0.000134	0.00066	CcSEcCtD
Dabrafenib—Nausea—Etoposide—uterine cancer	0.000133	0.000654	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—uterine cancer	0.000133	0.000653	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—uterine cancer	0.000132	0.000647	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—uterine cancer	0.000131	0.000644	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—uterine cancer	0.000131	0.000644	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00013	0.00064	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—uterine cancer	0.000128	0.00063	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—uterine cancer	0.000128	0.000627	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—uterine cancer	0.000126	0.000618	CcSEcCtD
Dabrafenib—Infection—Epirubicin—uterine cancer	0.000125	0.000614	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—uterine cancer	0.000124	0.000611	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—uterine cancer	0.000123	0.000606	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—uterine cancer	0.000123	0.000605	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—uterine cancer	0.000123	0.000604	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—uterine cancer	0.000122	0.0006	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—uterine cancer	0.000122	0.000597	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—uterine cancer	0.000121	0.000596	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—uterine cancer	0.000121	0.000596	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000121	0.000592	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—uterine cancer	0.000119	0.000583	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—uterine cancer	0.000118	0.000577	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—uterine cancer	0.000116	0.000571	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—uterine cancer	0.000116	0.000568	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000115	0.000563	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—uterine cancer	0.000114	0.00056	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—uterine cancer	0.000114	0.000559	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—uterine cancer	0.000114	0.000559	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—uterine cancer	0.000113	0.000555	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—uterine cancer	0.000113	0.000552	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—uterine cancer	0.000109	0.000537	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—uterine cancer	0.000109	0.000534	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000109	0.000533	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—uterine cancer	0.000108	0.000532	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—uterine cancer	0.000108	0.000528	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000106	0.000521	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—uterine cancer	0.000105	0.000517	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—uterine cancer	0.000103	0.000505	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—uterine cancer	0.000101	0.000497	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000101	0.000493	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—uterine cancer	0.0001	0.000493	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—uterine cancer	9.96e-05	0.000489	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—uterine cancer	9.95e-05	0.000488	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—uterine cancer	9.95e-05	0.000488	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—uterine cancer	9.52e-05	0.000467	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—uterine cancer	9.27e-05	0.000455	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—uterine cancer	9.2e-05	0.000452	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—uterine cancer	9.2e-05	0.000452	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—uterine cancer	9.03e-05	0.000443	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—uterine cancer	8.9e-05	0.000437	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—uterine cancer	8.61e-05	0.000423	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—uterine cancer	8.58e-05	0.000421	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—uterine cancer	8.35e-05	0.00041	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—uterine cancer	8.32e-05	0.000408	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—uterine cancer	8.24e-05	0.000404	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—uterine cancer	8e-05	0.000393	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—uterine cancer	7.97e-05	0.000391	CcSEcCtD
Dabrafenib—Rash—Epirubicin—uterine cancer	7.93e-05	0.000389	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—uterine cancer	7.93e-05	0.000389	CcSEcCtD
Dabrafenib—Headache—Epirubicin—uterine cancer	7.88e-05	0.000387	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—uterine cancer	7.7e-05	0.000378	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—uterine cancer	7.47e-05	0.000367	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—uterine cancer	7.4e-05	0.000363	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—uterine cancer	7.34e-05	0.00036	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—uterine cancer	7.33e-05	0.00036	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—uterine cancer	7.29e-05	0.000358	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—uterine cancer	6.92e-05	0.000339	CcSEcCtD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	3.01e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—AKT1—uterine cancer	3e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	3e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—AKT1—uterine cancer	3e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FBXW7—uterine cancer	2.97e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—AKT1—uterine cancer	2.97e-05	0.000172	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—DCN—uterine cancer	2.96e-05	0.000171	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—AKT1—uterine cancer	2.95e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—AKT1—uterine cancer	2.94e-05	0.00017	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR2—uterine cancer	2.93e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—AKT1—uterine cancer	2.93e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	2.91e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—uterine cancer	2.9e-05	0.000168	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.87e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—NRAS—uterine cancer	2.86e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—AKT1—uterine cancer	2.83e-05	0.000164	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTHFR—uterine cancer	2.82e-05	0.000163	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—RRM2—uterine cancer	2.82e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.82e-05	0.000163	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP11A1—uterine cancer	2.79e-05	0.000161	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—KRAS—uterine cancer	2.77e-05	0.00016	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—DCN—uterine cancer	2.74e-05	0.000159	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.73e-05	0.000158	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KRAS—uterine cancer	2.72e-05	0.000157	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.71e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDH1—uterine cancer	2.7e-05	0.000156	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—ERBB2—uterine cancer	2.68e-05	0.000155	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKR1B1—uterine cancer	2.68e-05	0.000155	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—STAR—uterine cancer	2.68e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	2.66e-05	0.000154	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.65e-05	0.000153	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SOCS3—uterine cancer	2.64e-05	0.000153	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKR1C3—uterine cancer	2.63e-05	0.000152	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STK11—uterine cancer	2.63e-05	0.000152	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KRAS—uterine cancer	2.61e-05	0.000151	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP11A1—uterine cancer	2.58e-05	0.000149	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	2.54e-05	0.000147	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—uterine cancer	2.51e-05	0.000145	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.51e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—PIK3CA—uterine cancer	2.5e-05	0.000145	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SOCS3—uterine cancer	2.46e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—KRAS—uterine cancer	2.46e-05	0.000142	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKR1C3—uterine cancer	2.44e-05	0.000141	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PIK3CA—uterine cancer	2.4e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ERBB2—uterine cancer	2.37e-05	0.000137	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.37e-05	0.000137	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—uterine cancer	2.36e-05	0.000136	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN2B—uterine cancer	2.36e-05	0.000136	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—uterine cancer	2.35e-05	0.000136	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CTNNB1—uterine cancer	2.35e-05	0.000136	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKR1C3—uterine cancer	2.34e-05	0.000135	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKR1B1—uterine cancer	2.33e-05	0.000135	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—STAR—uterine cancer	2.33e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN2B—uterine cancer	2.33e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—uterine cancer	2.31e-05	0.000134	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.31e-05	0.000134	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—uterine cancer	2.29e-05	0.000133	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1R—uterine cancer	2.29e-05	0.000133	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PGR—uterine cancer	2.28e-05	0.000132	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB2—uterine cancer	2.28e-05	0.000132	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—uterine cancer	2.22e-05	0.000129	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.2e-05	0.000127	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR2—uterine cancer	2.2e-05	0.000127	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1B—uterine cancer	2.19e-05	0.000127	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EP300—uterine cancer	2.18e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—YWHAE—uterine cancer	2.17e-05	0.000126	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMAD3—uterine cancer	2.15e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—EP300—uterine cancer	2.14e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SMAD3—uterine cancer	2.13e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1B—uterine cancer	2.11e-05	0.000122	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POLD1—uterine cancer	2.1e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—uterine cancer	2.09e-05	0.000121	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.08e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FBXW7—uterine cancer	2.08e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CTNNB1—uterine cancer	2.07e-05	0.00012	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—uterine cancer	2.07e-05	0.00012	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR2—uterine cancer	2.05e-05	0.000119	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—STK11—uterine cancer	2.05e-05	0.000119	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP19A1—uterine cancer	2.05e-05	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—AKT1—uterine cancer	2.04e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NRAS—uterine cancer	2.04e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR2—uterine cancer	2.03e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—uterine cancer	2.03e-05	0.000117	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.02e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PTEN—uterine cancer	2.02e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NRAS—uterine cancer	2e-05	0.000116	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.99e-05	0.000115	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.99e-05	0.000115	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.96e-05	0.000114	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—uterine cancer	1.96e-05	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—uterine cancer	1.95e-05	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PTEN—uterine cancer	1.94e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EP300—uterine cancer	1.93e-05	0.000112	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.93e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—STK11—uterine cancer	1.9e-05	0.00011	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP19A1—uterine cancer	1.9e-05	0.00011	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB2—uterine cancer	1.84e-05	0.000107	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.84e-05	0.000106	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POLD1—uterine cancer	1.83e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STK11—uterine cancer	1.82e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—uterine cancer	1.81e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—uterine cancer	1.8e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.77e-05	0.000103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ESR1—uterine cancer	1.76e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—uterine cancer	1.76e-05	0.000102	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RRM2—uterine cancer	1.75e-05	0.000101	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—uterine cancer	1.73e-05	0.0001	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—uterine cancer	1.72e-05	9.97e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKR1C1—uterine cancer	1.71e-05	9.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1B—uterine cancer	1.71e-05	9.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SOCS3—uterine cancer	1.7e-05	9.86e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DCN—uterine cancer	1.7e-05	9.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—uterine cancer	1.64e-05	9.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN2B—uterine cancer	1.63e-05	9.44e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.63e-05	9.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—uterine cancer	1.61e-05	9.32e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.6e-05	9.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1R—uterine cancer	1.58e-05	9.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—uterine cancer	1.58e-05	9.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.58e-05	9.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—uterine cancer	1.57e-05	9.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—uterine cancer	1.55e-05	8.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—uterine cancer	1.55e-05	8.95e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—uterine cancer	1.54e-05	8.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—uterine cancer	1.53e-05	8.86e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RRM2—uterine cancer	1.53e-05	8.83e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.51e-05	8.75e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EP300—uterine cancer	1.5e-05	8.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—uterine cancer	1.49e-05	8.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—uterine cancer	1.49e-05	8.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMAD3—uterine cancer	1.49e-05	8.62e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DCN—uterine cancer	1.48e-05	8.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—uterine cancer	1.47e-05	8.48e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.44e-05	8.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STAR—uterine cancer	1.44e-05	8.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—uterine cancer	1.43e-05	8.29e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—uterine cancer	1.43e-05	8.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—uterine cancer	1.43e-05	8.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR2—uterine cancer	1.42e-05	8.22e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—uterine cancer	1.4e-05	8.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP11A1—uterine cancer	1.4e-05	8.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—uterine cancer	1.38e-05	7.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—uterine cancer	1.37e-05	7.92e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.36e-05	7.86e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.33e-05	7.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—uterine cancer	1.32e-05	7.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—uterine cancer	1.32e-05	7.63e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKR1C3—uterine cancer	1.32e-05	7.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—uterine cancer	1.29e-05	7.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—uterine cancer	1.29e-05	7.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—uterine cancer	1.28e-05	7.4e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—uterine cancer	1.28e-05	7.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—uterine cancer	1.27e-05	7.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—uterine cancer	1.27e-05	7.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—uterine cancer	1.22e-05	7.08e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—uterine cancer	1.22e-05	7.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—uterine cancer	1.22e-05	7.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—uterine cancer	1.21e-05	6.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—uterine cancer	1.21e-05	6.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—uterine cancer	1.19e-05	6.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—uterine cancer	1.18e-05	6.83e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—STK11—uterine cancer	1.18e-05	6.82e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.18e-05	6.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—uterine cancer	1.18e-05	6.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—uterine cancer	1.16e-05	6.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—uterine cancer	1.15e-05	6.65e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—uterine cancer	1.13e-05	6.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POLD1—uterine cancer	1.13e-05	6.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—uterine cancer	1.12e-05	6.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—uterine cancer	1.12e-05	6.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—uterine cancer	1.12e-05	6.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—uterine cancer	1.11e-05	6.41e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.11e-05	6.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—uterine cancer	1.1e-05	6.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—uterine cancer	1.09e-05	6.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—uterine cancer	1.07e-05	6.19e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.06e-05	6.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.05e-05	6.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—uterine cancer	1.05e-05	6.08e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—uterine cancer	1.05e-05	6.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—uterine cancer	1.04e-05	6e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—STK11—uterine cancer	1.03e-05	5.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP19A1—uterine cancer	1.03e-05	5.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—uterine cancer	1.03e-05	5.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—uterine cancer	9.94e-06	5.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—uterine cancer	9.89e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—uterine cancer	9.81e-06	5.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—uterine cancer	9.7e-06	5.61e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RRM2—uterine cancer	9.4e-06	5.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DCN—uterine cancer	9.13e-06	5.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—uterine cancer	9.09e-06	5.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—uterine cancer	9.05e-06	5.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—uterine cancer	9.04e-06	5.23e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—uterine cancer	9e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—uterine cancer	8.92e-06	5.16e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—uterine cancer	8.86e-06	5.12e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP11A1—uterine cancer	8.6e-06	4.97e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—uterine cancer	8.57e-06	4.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—uterine cancer	8.46e-06	4.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—uterine cancer	8.45e-06	4.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—uterine cancer	8.41e-06	4.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—uterine cancer	8.35e-06	4.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—uterine cancer	8.3e-06	4.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—uterine cancer	8.27e-06	4.78e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—uterine cancer	8.18e-06	4.73e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKR1C3—uterine cancer	8.12e-06	4.7e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—uterine cancer	7.94e-06	4.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—uterine cancer	7.81e-06	4.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.8e-06	4.52e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—uterine cancer	7.76e-06	4.49e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—uterine cancer	7.72e-06	4.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—uterine cancer	7.68e-06	4.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—uterine cancer	7.67e-06	4.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—uterine cancer	7.61e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—uterine cancer	7.57e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—uterine cancer	7.51e-06	4.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—uterine cancer	7.42e-06	4.3e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—uterine cancer	7.35e-06	4.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—uterine cancer	7.26e-06	4.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—uterine cancer	7.18e-06	4.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—uterine cancer	7.09e-06	4.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—uterine cancer	6.87e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—uterine cancer	6.79e-06	3.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—uterine cancer	6.78e-06	3.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—uterine cancer	6.34e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STK11—uterine cancer	6.33e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP19A1—uterine cancer	6.33e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—uterine cancer	6.26e-06	3.62e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—uterine cancer	6.05e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—uterine cancer	5.84e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—uterine cancer	5.6e-06	3.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—uterine cancer	5.37e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—uterine cancer	5.19e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—uterine cancer	4.97e-06	2.87e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—uterine cancer	4.94e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—uterine cancer	4.93e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—uterine cancer	4.75e-06	2.75e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—uterine cancer	4.7e-06	2.72e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—uterine cancer	4.58e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—uterine cancer	4.39e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—uterine cancer	4.29e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—uterine cancer	4.09e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—uterine cancer	3.48e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—uterine cancer	3.03e-06	1.75e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—uterine cancer	2.84e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—uterine cancer	2.64e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—uterine cancer	2.52e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—uterine cancer	2.47e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.87e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—uterine cancer	1.52e-06	8.82e-06	CbGpPWpGaD
